Sunshine Biopharma Enters Into a Collaboration Agreement With a Leading Lipid Nanoparticle Formulation Company for Its K1.1 Anticancer MRNA Project
Sunshine Biopharma Enters Into a Collaboration Agreement With a Leading Lipid Nanoparticle Formulation Company for Its K1.1 Anticancer MRNA Project
MONTREAL, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: "SBFM"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas, including oncology and antivirals today announced that it has entered into a collaboration agreement with one of North America's leading lipid nanoparticle ("LNP") companies. The purpose of the collaboration is to advance the development of Sunshine Biopharma's mRNA-based anticancer macromolecule, K1.1.
蒙特利爾，2022 年 11 月 16 日（GLOBE NEWSWIRE）-陽光生物製藥股份有限公司（NASDAQ：「SBFM」），一家在包括腫瘤和抗病毒藥物在內的各種治療領域提供和研究救生藥物的製藥公司，今天宣布與北美領先的脂質納米顆粒（LNP）公司之一達成合作協議。此次合作的目的是促進陽光生物製藥基於 MRNA 的抗癌高分子 K1.1 的開發。
The Company's collaboration partner will prepare two LNP formulations (K1.1a and K1.1b) of Sunshine Biopharma's in-house developed antineoplastic mRNA, K1.1. Sunshine Biopharma had previously shown that its K1.1 mRNA is capable of destroying cancer cells in vitro, including multidrug resistant breast cancer cells (MCF-7/MDR), ovarian adenocarcinoma cells (OVCAR-3), and pancreatic cancer cells (SUIT-2). Parallel studies using normal human cells (HMEC) showed that K1.1 mRNA had little or no cytotoxic effects.
該公司的合作夥伴將準備兩種 LNP 配方（K1.1a 和 K1.1b）的陽光生物製藥公司內部開發的抗腫瘤 mRNA，K1.1。陽光生物製藥先前已顯示其 K1.1 mRNA 能夠破壞體外癌細胞，包括多重抗藥性乳腺癌細胞（MCF-7/MDR）、卵巢腺癌細胞（OVCAR-3）和胰腺癌細胞（SUIT-2）。使用正常人體細胞（HMEC）的並行研究表明，K1.1 mRNA 很少或沒有細胞毒性作用。
The partner generated K1.1a::LNP and K1.1b::LNP will be used to conduct in vivo studies on xenograft mice expressing the in vitro tested human cancers as well as liver cancer. Should these mice studies prove successful, the Company can advance relatively rapidly to conducting human trials. The LNP formulated K1.1 mRNA can be readily adapted for delivery into patients using the recently gained knowledge from the mRNA vaccine technology.
該合作夥伴產生的 K1.1a:: LNP 和 K1.1b:: LNP 將用於對異種移植小鼠進行體外研究，表達經體外測試的人類癌症以及肝癌。如果這些小鼠研究證明成功，公司可以相對迅速地進行人體試驗。LNP 制定的 K1.1 mRNA 可以使用最近從 mRNA 疫苗技術獲得的知識，輕鬆適應患者的輸送。
"We are delighted to be working with our new partner and their fully integrated team of experts in LNP technology," said Dr. Steve Slilaty, CEO of Sunshine Biopharma.
陽光生物製藥公司執行長 Steve Silaty 博士表示：「我們很高興能與我們的新合作夥伴以及他們完全整合的 LNP 技術專家團隊合作。
About Sunshine Biopharma Inc.
關於陽光生物製藥
Sunshine Biopharma recently acquired Nora Pharma Inc. and as a result the Company now has 36 employees and 50 generic prescription drugs on the market in Canada. In parallel, Sunshine Biopharma is continuing its drug development R&D program. In addition to the K1.1 anticancer mRNA project, the Company is working on the development Adva-27a, a small molecule having the unique ability to destroy multidrug resistant cancer cells, including pancreatic cancer cells, small-cell lung cancer cells, breast cancer cells, and uterine sarcoma cells. Clinical trials for pancreatic cancer indication are planned to be conducted at McGill University's Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is also engaged in the development of a COVID-19 treatment in collaboration with the University of Arizona. The project, currently in advanced stages of preclinical studies, is focused on the development of an inhibitors for SARS-CoV-2 PLpro protease. PLpro is unique to the SARS group of Coronaviruses and is responsible for suppressing the human immune system making this group of viruses more deadly.
陽光生物製藥最近收購了諾拉製藥公司，因此該公司目前在加拿大市場上擁有 36 名員工和 50 種通用處方藥。同時，陽光生物製藥正在繼續其藥物開發研發計劃。除了 K1.1 抗癌 mRNA 項目外，公司還致力於開發 Adva-27a，這是一種具有獨特能力破壞多種抗藥性癌細胞的小分子，包括胰腺癌細胞，小細胞肺癌細胞，乳腺癌細胞和子宮肉瘤細胞。胰臟癌適應症的臨床試驗計劃在加拿大蒙特利爾的麥吉爾大學猶太綜合醫院進行。陽光生物製藥還與亞利桑那大學合作開發 COVID-19 治療方案。該項目目前處於臨床前研究的高級階段，專注於開發 SARS-CoV-2 PLPro 蛋白酶抑製劑。PLPro 是 SARS 冠狀病毒組所獨有的，負責抑制人體免疫系統，使這組病毒更加致命。
Safe Harbor Forward-Looking Statements
安全港前瞻性陳述
This press release contains forward-looking statements which are based on current expectations, forecasts, and assumptions of Sunshine Biopharma, Inc. (the "Company") that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, including statements related to the Company's drug development activities, financial performance, and future growth. These risks and uncertainties are further described in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in the Company's filings with the SEC. Reference is hereby made to cautionary statements and risk factors set forth in the Company's most recent SEC filings.
本新聞稿包含前瞻性陳述，基於 Sunshine Bioharma, Inc.（「本公司」）目前的預期、預測和假設，這些陳述涉及風險以及可能導致實際結果和結果與預期結果有重大差異的不確定性。這些聲明出現在此版本中的多個地方，包括所有不是關於公司意圖，信念或當前預期的歷史事實陳述，包括與公司藥物開發活動，財務績效和未來增長相關的聲明。這些風險和不確定性在本公司向美國證券交易委員會（SEC）提交的文件和報告中進一步描述。實際結果和某些事件的時間可能與前瞻性陳述中預計或預計的事件有很大不同，這是由於公司向 SEC 提交的文件中不時詳述了一些因素。特此參考公司最近的 SEC 文件中列出的警示聲明和風險因素。
For Additional Information:
如需其他資訊：
Sunshine Biopharma Contact:
Camille Sebaaly, CFO
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
陽光生物製藥聯絡方式：
卡米爾·西巴利，首席財務官
直線電話：514-814-0464
camille.sebaaly@sunshinebiopharma.com
Sunshine Biopharma Media Contact:
Christine Petraglia
TraDigital IR
Direct Line: 917-633-8980
investors@sunshinebiopharma.com
陽光生物製藥媒體聯絡人：
克莉絲汀·佩特拉利亞
紅外線
直線電話：917-633-8980
investors@sunshinebiopharma.com
譯文內容由第三人軟體翻譯。